Replies to post #51558 on Biotech Values

[genisi]

BPA
Don't know when does the formulation patent run out, I think they are using Antares Pharma's formolation. But since LibiGel is bioidentical testosterone, I don't see what will stop physicians from prescribing generic versions of similar compounds to treat FSD. So far, as reported by BDY, Elestrin (BPA's first product), is not selling very well and Libigel will face the same sort of generic challengers IMO.